Category
Big Data Analysis
Articles in this category

8/18/2026
EMA and HMA Open Consultation on EMRN Data Standards Framework
EMA and HMA have opened a public consultation on the draft EMRN Data Standards Framework, which sets out how the EU will govern data standards for medicines regulation. Comments close 18 September 2026.
Read Article →
8/17/2026
NICE DSU and EEPRU Release Mapping Tools Ahead of EQ-5D-5L Value Set Adoption
The NICE Decision Support Unit and EEPRU have released updated Stata, Excel and R commands for mapping EQ-5D-3L data to the new EQ-5D-5L value set, giving UK HTA analysts a validated route to convert legacy three-level utility data ahead of NICE's adoption of the five-level value set.
Read Article →
8/13/2026
EMA Qualifies Big MS Data Network for Post-Authorization Safety Studies
How can real-world data networks improve safety evaluations for multiple sclerosis therapies?
A new collaborative MS data initiative is enabling more robust assessments of treatment safety by pooling patient insights across sources.
Discover how this approach is advancing evidence generation in neurology.
#SyenzaNews #digitalhealth #clinicaltrials #datascience #innovation
Read Article →
8/4/2026
Dutch health fund projected to post €1.34bn deficit in 2026 after three surplus years
Is the Dutch health insurance fund heading back into the red?
Projections show the Zorgverzekeringsfonds returning to an operating deficit in 2026, raising fresh questions about long-term sustainability and the balance between premiums, benefits, and public spending.
Read the full analysis to see what this means for healthcare financing.
#SyenzaNews #healthcare #HealthEconomics #MarketAccess #healthcarepolicy
Read Article →
7/31/2026
China Boosts Global Innovative Drug Pipeline Post-2016 Reforms
🚀 What sparked China's pharmaceutical innovation surge after 2016?
Key regulatory reforms streamlined approvals and accelerated R&D, rapidly elevating the country’s role in global drug development.
Explore the data and trends behind this transformation.
#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess
Read Article →
7/20/2026
Brazil pharmaceutical supply chain vulnerabilities exposed by pandemic disruptions
🔍 How did the pandemic expose critical weaknesses in Brazil’s pharmaceutical supply chain?
From raw-material dependencies to distribution bottlenecks, COVID-19 disruptions laid bare vulnerabilities that continue to threaten medicine availability and market access across the region.
Read the full analysis to see what these lessons mean for building more resilient supply systems.
#SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy
Read Article →
7/15/2026
Digital Medical Device Regulations Enable Rapid Approvals
🚀 What if smarter regulations could fast-track digital medical device approvals?
Recent updates are streamlining pathways for MedTech innovators, cutting timelines while maintaining rigorous safety standards. This shift is accelerating patient access to next-generation health technologies.
Read the full analysis to see what it means for your pipeline.
#SyenzaNews #medicaldevices #regulatoryaffairs #innovation #DigitalTransformation
Read Article →
7/13/2026
Portuguese Hospital Data Platform Enables Population Health Analysis
📊 How is Portugal turning hospital data into powerful population health insights?
A new data platform is enabling deeper analysis of health trends, outcomes, and resource use across patient populations.
Explore how this approach is advancing data-driven decision-making in healthcare.
#SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #datascience
Read Article →
6/6/2026
Mifepristone Safety Study: Ensuring Continued Regulatory Oversight
Who’s watching mifepristone’s safety data—and why it matters? 🔬⚖️
A recent safety study reconfirms mifepristone’s established safety profile but highlights gaps in post‑market surveillance and regulatory transparency. These findings could influence oversight practices, prescribing guidance, and access for patients.
Read the full article for a clear breakdown of the data, regulatory implications, and what stakeholders should watch next.
#SyenzaNews #regulatoryaffairs #pharmaceuticals #healthcarepolicy #governance
Read Article →
5/22/2026
Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report
Curious how clinical trial monitoring in the EU/EEA shifted in Q1 2026? 🔍
This report distills emerging trends — from increased risk-based and centralized/remote monitoring to regulator scrutiny on data integrity and common inspection findings — plus practical recommendations for sponsors and CROs to stay compliant and efficient.
Read the full Q1 2026 insights to see what actions your team should prioritise next.
#SyenzaNews #clinicaltrials #regulatoryaffairs #DigitalTransformation #healthcarepolicy
Read Article →
5/19/2026
Healthcare Innovation Trends: Insights from the Healthcare Economics Conference in Lisbon
Is Lisbon the next European hub for healthcare innovation? 📍🚀
From a surge in HealthTech startups and AI-driven care pilots to stronger public–private partnerships and EU-backed funding, Lisbon is turning research excellence into scalable healthcare solutions.
Read the full piece for the trends, opportunities, and practical takeaways shaping the region’s health ecosystem.
#SyenzaNews #HealthcareInnovation #HealthTech #innovation #DigitalTransformation
Read Article →
4/28/2026
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced Predictive Insights
Can TikTok signals help forecast opioid overdoses before they surge? 🔍📈
This piece highlights how combining TikTok trends with machine learning can provide early-warning signals for opioid overdose trends—boosting situational awareness for public health teams while surfacing privacy and bias challenges.
Read the full article to explore the predictive methods, real-world findings, and what this means for policymakers and healthcare responders.
#SyenzaNews #AIinHealthcare #digitalhealth #datascience #ai
Read Article →


